A Method for Stabilizing the Proportion of the Reduced Form of Albumin During Cell-Free and Concentrated Ascites Reinfusion Therapy in Patients with Malignant Ascites

Atsushi Ohashi, Shigeru Nakai, Sachie Yamada, Masao Kato, Midori Hasegawa

研究成果: Article

1 引用 (Scopus)

抜粋

Cell-free and concentrated ascites reinfusion therapy (CART) is used to treat malignant ascites. However, the qualities of albumin in malignant ascites, such as antioxidative activity, may decrease owing to oxidative stress caused by cancer cells and inflammatory reactions. We investigated the fraction percentages of mercaptalbumin (HMA%, reduced form) and non-mercaptalbumin (HNA%, oxidized form) in malignant ascites from 21 patients who received CART and compared the HMA% in the malignant ascites and human serum albumin (HSA) preparations. HMA% of albumin in malignant ascites (22.5%) was significantly lower than that in HSA preparation (42.2%). To ensure a high HMA%, we added L-cysteine to the paracentesis-treated ascites followed by dialysis 1 h later. As a result, the HMA% of albumin in malignant ascites was increased to 59.1%. Our results suggest that using this method in CART will improve patient's albumin quality.

元の言語English
ページ(範囲)242-247
ページ数6
ジャーナルTherapeutic Apheresis and Dialysis
23
発行部数3
DOI
出版物ステータスPublished - 06-2019

All Science Journal Classification (ASJC) codes

  • Hematology
  • Nephrology

フィンガープリント A Method for Stabilizing the Proportion of the Reduced Form of Albumin During Cell-Free and Concentrated Ascites Reinfusion Therapy in Patients with Malignant Ascites' の研究トピックを掘り下げます。これらはともに一意のフィンガープリントを構成します。

  • これを引用